Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.

Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma. - Long term follow-up study of gefitinib vs erlotinib for lung adenocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030082

Enrollment

561

Registered

2017-11-22

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously treated advanced lung adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients expressing informed consents with WJOG5108LFS study who were enrolled into original WJOG5108L study

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival of patients with activating mutation according to treatment arm	—

Secondary

Measure	Time frame
Efficacy of brain metastasis in patients with brain metastasis according to treatment arm	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results